ACELRX PHARMACEUTICALS INC (ACRX) Stock Price, Quote, News and Overview
NASDAQ:ACRX - Nasdaq - US00444T2096 - Common Stock - Currency: USD
ACRX Quote, Performance and Key Statistics
0.86
+0.06 (+7.5%)
The current stock price of ACRX is 0.86 USD. In the past month the price increased by 18.03%. In the past year, price decreased by -66.8%.
ACRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ACRX
Company Profile
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
Company Info
ACELRX PHARMACEUTICALS INC
1850 Gateway Drive, Suite 175
San Mateo CALIFORNIA 94063 US
CEO: Vincent J. Angotti
Employees: 19
Company Website: https://www.acelrx.com
Phone: 16502163500
ACELRX PHARMACEUTICALS INC / ACRX FAQ
What is the stock price of ACELRX PHARMACEUTICALS INC today?
The current stock price of ACRX is 0.86 USD. The price increased by 7.5% in the last trading session.
What is the ticker symbol for ACELRX PHARMACEUTICALS INC stock?
The exchange symbol of ACELRX PHARMACEUTICALS INC is ACRX and it is listed on the Nasdaq exchange.
On which exchange is ACRX stock listed?
ACRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACELRX PHARMACEUTICALS INC stock?
8 analysts have analysed ACRX and the average price target is 4.72 USD. This implies a price increase of 448.55% is expected in the next year compared to the current price of 0.86. Check the ACELRX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACELRX PHARMACEUTICALS INC worth?
ACELRX PHARMACEUTICALS INC (ACRX) has a market capitalization of 14.58M USD. This makes ACRX a Nano Cap stock.
How many employees does ACELRX PHARMACEUTICALS INC have?
ACELRX PHARMACEUTICALS INC (ACRX) currently has 19 employees.
What are the support and resistance levels for ACELRX PHARMACEUTICALS INC (ACRX) stock?
ACELRX PHARMACEUTICALS INC (ACRX) has a support level at 0.78. Check the full technical report for a detailed analysis of ACRX support and resistance levels.
Is ACELRX PHARMACEUTICALS INC (ACRX) expected to grow?
The Revenue of ACELRX PHARMACEUTICALS INC (ACRX) is expected to decline by -91.49% in the next year. Check the estimates tab for more information on the ACRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ACELRX PHARMACEUTICALS INC (ACRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACRX, evaluating the profitability, health, valuation and growth aspects
- ACELRX PHARMACEUTICALS INC (ACRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACELRX PHARMACEUTICALS INC (ACRX) Sales and EPS estimates to see what analysts future expectations are.
- ACELRX PHARMACEUTICALS INC (ACRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACELRX PHARMACEUTICALS INC (ACRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACELRX PHARMACEUTICALS INC (ACRX) Stock Chart to make your own analysis
- ACELRX PHARMACEUTICALS INC (ACRX) Latest news and press-releases to stay up to date.
Does ACELRX PHARMACEUTICALS INC (ACRX) stock pay dividends?
ACRX does not pay a dividend.
When does ACELRX PHARMACEUTICALS INC (ACRX) report earnings?
ACELRX PHARMACEUTICALS INC (ACRX) will report earnings on 2024-03-28, after the market close.
What is the Price/Earnings (PE) ratio of ACELRX PHARMACEUTICALS INC (ACRX)?
ACELRX PHARMACEUTICALS INC (ACRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.23).
ACRX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ACRX. When comparing the yearly performance of all stocks, ACRX is a bad performer in the overall market: 81.14% of all stocks are doing better.
ACRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACRX. The financial health of ACRX is average, but there are quite some concerns on its profitability.
ACRX Financial Highlights
Over the last trailing twelve months ACRX reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 50.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113.65% | ||
| ROE | -144.7% | ||
| Debt/Equity | 0 |
ACRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ACRX. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 72.27% and a revenue growth -91.49% for ACRX